Skip to main content
Premium Trial:

Request an Annual Quote

John Molloy, Mark Poznansky, Cheryl Reicin, Niclas Stiernholm

Premium

The Ontario Genomics Institute has named five new directors to its board: John Molloy, president and chief executive officer of Parteq Innovations; Mark Poznansky, president and scientific director of the Robarts Research Institute; Cheryl Reicin, practice leader of the technology and life sciences group at Torys; Niclas Stiernholm, chief executive officer of Trillium Therapeutics; and Brian Underdown, managing director of technology investing at MDS Capital.

Molloy holds an MBA from Queen's University, Poznansky received a PhD in physiology from McGill University, Reicin has a JD from Harvard Law School and a BA from Columbia University, Stiernholm holds a PhD in immunology from the University of Toronto, and Underdown has a PhD in immunology from Washington University in St. Louis.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.